Compounds > kynurenic acid

kynurenic acid and levodopa

kynurenic acid has been researched along with levodopa in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (80.00)29.6817
2010's1 (20.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J1
Rassoulpour, A; Schwarcz, R; Wu, HQ1
Bédard, PJ; Grégoire, L; Guidetti, P; Izzo, E; Rassoulpour, A; Samadi, P; Schwarcz, R1
Bédard, PJ; Di Paolo, T; Grégoire, L; Guidetti, P; Izzo, E; Rassoulpour, A; Samadi, P; Schwarcz, R1
Fukuda, K1

Other Studies

5 other study(ies) available for kynurenic acid and levodopa

ArticleYear
Chemical genetics reveals a complex functional ground state of neural stem cells.
    Nature chemical biology, 2007, Volume: 3, Issue:5

    Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells

2007
Effect of systemic L-DOPA administration on extracellular kynurenate levels in the rat striatum.
    Journal of neural transmission (Vienna, Austria : 1996), 2002, Volume: 109, Issue:3

    Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Astrocytes; Dopamine; Dose-Response Relationship, Drug; Down-Regulation; Extracellular Space; Kynurenic Acid; Levodopa; Male; Neostriatum; Neurons; Neurotoxins; Oxidopamine; Parkinson Disease; Quinolinic Acid; Rats; Rats, Sprague-Dawley; Receptors, Dopamine; Receptors, N-Methyl-D-Aspartate; Receptors, Nicotinic; Substantia Nigra

2002
Effect of kynurenine 3-hydroxylase inhibition on the dyskinetic and antiparkinsonian responses to levodopa in Parkinsonian monkeys.
    Movement disorders : official journal of the Movement Disorder Society, 2005, Volume: 20, Issue:7

    Topics: Analysis of Variance; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Female; Kynurenic Acid; Kynurenine 3-Monooxygenase; Levodopa; Macaca fascicularis; Mixed Function Oxygenases; Motor Activity; Parkinsonian Disorders; Quinolinic Acid; Sulfonamides; Thiazoles; Time Factors

2005
Prolonged kynurenine 3-hydroxylase inhibition reduces development of levodopa-induced dyskinesias in parkinsonian monkeys.
    Behavioural brain research, 2008, Jan-25, Volume: 186, Issue:2

    Topics: Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Drug Interactions; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Female; Kynurenic Acid; Kynurenine; Kynurenine 3-Monooxygenase; Levodopa; Macaca fascicularis; Motor Activity; Parkinsonian Disorders; Quinolinic Acid; Sulfonamides; Thiazoles; Time Factors

2008
Integrated theory to unify status among schizophrenia and manic depressive illness.
    Medical hypotheses, 2015, Volume: 85, Issue:4

    Topics: 5-Hydroxytryptophan; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Biopterins; Bipolar Disorder; Blood-Brain Barrier; Depression; Depression, Postpartum; Dopamine; Female; Hallucinations; Humans; Kynurenic Acid; Levodopa; Male; Neuroleptic Malignant Syndrome; Neurotransmitter Agents; Paranoid Disorders; Premenstrual Syndrome; Schizophrenia; Seasonal Affective Disorder; Serotonin; Serotonin Syndrome; Tyrosine

2015